Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD

Blood (2019) 134 (Supplement_1): 3899.

https://doi.org/10.1182/blood-2019-130203

Published: 2019

Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Tara L Lin, MD, Carlos E Vigil, MD, Andrew Dalovisio, MD, Eunice S. Wang, MD, Moshe Yair Levy, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD, Pau Montesinos, MD PhD, Juan Miguel Miguel Bergua Burgues, Jeffrey R. Schriber, MD, Stephen Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD

Blood (2018) 132 (Supplement 1): 30.

https://doi.org/10.1182/blood-2018-99-115018

Published: 2018

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Direct Comparison of in-Vitro Growth of Primary Human Acute Myeloid Leukemia (AML) Cells in Stromal and Stromal-Free Conditions

Jing Chen, MD, Glorymar Ibanez-Sanchez, Paul Calder, Mark G. Frattini, MD PhD

Blood (2018) 132 (Supplement 1): 5096.

https://doi.org/10.1182/blood-2018-99-116978

Published: 2018

Journal Articles

Stroma-Based Versus Stroma-Free Long-Term Survival and Proliferation of Primary Acute Myeloid Leukemia (AML) Cells

Jing Chen, MD, Glorymar Ibanez-Sanchez, Paul Calder, Mark G. Frattini, MD PhD

Blood (2017) 130 (Supplement 1): 5569.

https://doi.org/10.1182/blood.V130.Suppl_1.5569.5569

Published: 2017

Journal Articles

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

Blood (2017) 130 (Supplement 1): 1699.

https://doi.org/10.1182/blood.V130.Suppl_1.1699.1699

Published: 2017

Journal Articles

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Daniel J. Lee, MD, Todd L. Rosenblat, MD MS, Mark Lawrence Heaney, MD PhD, Joseph G. Jurcic, MD, Azra Raza, MD, Kristina Gazivoda, Katherine Harwood, Ryan Shelton, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2016) 128 (22): 2816.

https://doi.org/10.1182/blood.V128.22.2816.2816

Published: 2016

Journal Articles

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Todd Rosenblat, MD, Mark L. Heaney, MD PhD, Joseph G Jurcic, MD, Azra Raza, MD, John G. Mears, MD, Ruth Santos, BS, Diana Carrillo, BS, David Shum, MS, Jacquelyn Gonzales, BSN, RN, Kevin Zikaras, BS, Martin Santos, BS, Rong Zhang, MS, Glorymar Ibanezs, MS, Leah Hogdal, BA, Jennifer Crombie, MD, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony G. Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2014) 124 (21): 974.

https://doi.org/10.1182/blood.V124.21.974.974

Published: 2014

Journal Articles

Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression

Blood (2014) 124 (21): 1954.

https://doi.org/10.1182/blood.V124.21.1954.1954

Published: 2014

Journal Articles

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Jeffrey R Gardner, MBA, Sean Devlin, PhD, Kristina Knapp, Francesco Bauli, MS, Nicole Lamanna, MD, Mark G. Frattini, MD, PhD, Renier J Brentjens, MD, PhD, Peter G. Maslak, M.D., Joseph G. Jurcic, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2012) 120 (21): 2482.

https://doi.org/10.1182/blood.V120.21.2482.2482

Published: 2012

Journal Articles

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Elizabeth Halton, RN, MS, ANP, Dick Chung, BS, Kun Xiao, MS, MPH, Hilda Quintanilla, RN, MS, ANP, Christina Baldwin, RN, MS, ANP, Pamela Baird, RN, MS, ANP, Ellin Berman, MD, Renier J Brentjens, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Rana Kaplan, MD, Genovefa Papanicolaou, MD, Mark G. Frattini, MD, PhD

Blood (2012) 120 (21): 3556.

https://doi.org/10.1182/blood.V120.21.3556.3556

Published: 2012

Journal Articles

Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells

Marco L Davila, MD, PhD, Isabelle Riviere, PhD, Xiuyan Wang, PhD, Jae H. Park, MD, Jolanta Stefanski, Clare Taylor, MSc, Qing He, Malgorzata Olszewska, Teresa Wasielewska, Oriana Borquez-Ojeda, Jinrong Qu, Shirley Bartido, PhD, Joseph G. Jurcic, MD, Dan Douer, MD, Mark G. Frattini, MD, PhD, Michel Sadelain, MD, PhD, Renier J Brentjens, MD, PhD

Blood (2012) 120 (21): 3566.

https://doi.org/10.1182/blood.V120.21.3566.3566

Published: 2012

Journal Articles

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Suzanne M. Chanel, RN, Tao Dao, MD, PhD, Yvette Bernal, Joseph G. Jurcic, MD, Rhong Zhang, Pamela Simancek, Martin S Tallman, MD, David A. Scheinberg, MD, PhD, Peter G. Maslak, M.D.

Blood (2012) 120 (21): 3624.

https://doi.org/10.1182/blood.V120.21.3624.3624

Published: 2012

Journal Articles

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Nicole Lamanna, MD, Mark Weiss, MD, Ellin Berman, MD, Mark G. Frattini, MD, PhD, Mark Heaney, MD, PhD, Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Heather Landau, MD, Hanna Weissbrot, BA, Peter G. Maslak, M.D.

Blood (2012) 120 (21): 4293.

https://doi.org/10.1182/blood.V120.21.4293.4293

Published: 2012

Journal Articles

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Todd L. Rosenblat, MD, Michael R. McDevitt, PhD, Neeta Pandit-Taskar, MD, Jorge A. Carrasquillo, MD, Suzanne M. Chanel, RN, Kevin Zikaras, BS, Mark G. Frattini, MD, PhD, Peter G. Maslak, M.D., Dragan Cicic, MD, Steven M. Larson, MD, David A. Scheinberg, MD, PhD

Blood (2011) 118 (21): 768.

https://doi.org/10.1182/blood.V118.21.768.768

Published: 2011

Journal Articles

Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients

Thanh-Trang T Vo, MD, Richard Stone, MD, Daniel J DeAngelo, MD, PhD, Mark G. Frattini, MD, PhD, Anthony G. Letai, MD, PhD

Blood (2011) 118 (21): 239.

https://doi.org/10.1182/blood.V118.21.239.239

Published: 2011

Journal Articles

Preclinical Assessment of a Novel CDC7 Inhibitor: Genomewide RNAi Screening Identifies Unique Synergetic and Resistance Genes,

Nancy Liu-Sullivan, Bhavneet Bhinder, David Shum, Christina Ramirez, Constantin Radu, Hakim Djaballah, PhD, Mark G. Frattini, MD, PhD

Blood (2011) 118 (21): 3570.

https://doi.org/10.1182/blood.V118.21.3570.3570

Published: 2011

Journal Articles

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Ellin Berman, MD, Cyrus V. Hedvat, MD, PhD, Joseph G. Jurcic, MD, Mark Heaney, MD, PhD, Peter G. Maslak, M.D., Renier Brentjens, MD, PhD, Nicole Lamanna, MD, Todd L. Rosenblat, MD, Mark G. Frattini, MD, PhD, Ann A Jakubowski, MD, PhD, Suresh Jhanwar, PhD

Blood (2011) 118 (21): 4433.

https://doi.org/10.1182/blood.V118.21.4433.4433

Published: 2011

Journal Articles

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Jeffrey R Gardner, MBA, Kristina Knapp, Mark G. Frattini, MD, PhD, Nicole Lamanna, MD, Renier Brentjens, MD, PhD, Joseph G Jurcic, MD, Peter G. Maslak, M.D., Ellin Berman, MD, Mark Weiss, MD, David A. Scheinberg, MD, PhD, Mark Heaney, MD, PhD

Blood (2011) 118 (21): 1765.

https://doi.org/10.1182/blood.V118.21.1765.1765

Published: 2011

Journal Articles

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Kristen M O'Dwyer, M.D., David Shum, M.S., Mark Heaney, MD, PhD, Renier J. Brentjens, MD, PhD, Peter Maslak, MD, Joseph G Jurcic, MD, Hakim Djaballah, Ph.D., Mark G. Frattini, MD, PhD

Blood (2009) 114 (22): 2657.

https://doi.org/10.1182/blood.V114.22.2657.2657

Published: 2009

NARROW

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML)

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Direct Comparison of in-Vitro Growth of Primary Human Acute Myeloid Leukemia (AML) Cells in Stromal and Stromal-Free Conditions

Stroma-Based Versus Stroma-Free Long-Term Survival and Proliferation of Primary Acute Myeloid Leukemia (AML) Cells

Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies

Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression

Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.

Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy

Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells

Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR)

High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)

Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 ( 225 Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML)

Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients

Preclinical Assessment of a Novel CDC7 Inhibitor: Genomewide RNAi Screening Identifies Unique Synergetic and Resistance Genes,

Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center

Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History

Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only